Jasper Therapeutics(US:JSPR)2025-06-16 13:00Summary of Jasper Therapeutics Spotlight Data Update Conference Call Company Overview - Company: Jasper Therapeutics - Focus: Development of briquilimab for chronic inducible urticaria (Sindu) and other mast cell diseases Key Industry Insights - Industry: Biopharmaceuticals, specifically targeting mast cell-driven diseases - Condition: Chronic inducible urticaria (Sindu) is a debilitating skin condition with significant quality of life impacts and no approved treatments globally beyond antihistamines [6][8] Core Findings and Data - Clinical Trial: Phase Ib/IIa Spotlight clinical trial evaluating briquilimab in chronic inducible urticaria - Cohort Data: - 180 mg cohort: 100% clinical response rate, with 92% achieving complete response [11][12] - 120 mg cohort: 92% clinical response rate, with 83% achieving complete response [11][15] - Overall, 96% of patients across all doses achieved a clinical response, and 81% achieved a complete response [5] - Safety Profile: - Briquilimab was well tolerated with no serious adverse events reported at the 180 mg dose level [18][21] - Adverse events included nasopharyngitis, fatigue, and headache, all mild and transient [19][20] - Efficacy Timeline: - 67% of participants in the 180 mg cohort achieved a clinical response by week two [12] - 58% maintained clinical response at week eight [12][21] Additional Important Insights - Unmet Medical Need: Chronic inducible urticaria has a high unmet medical need, with significant impacts on patients' quality of life [6][8] - Mechanism of Action: Briquilimab targets KIT on mast cells, potentially offering a new treatment paradigm for mast cell diseases [21] - Future Studies: Plans for registrational studies in Sindu and chronic spontaneous urticaria (CSU) are underway, with a focus on advancing briquilimab into further clinical trials [22][23] - Upcoming Milestones: Full results from the Spotlight study are expected to be presented at a medical conference in the second half of 2025 [23] Conclusion - Jasper Therapeutics is making significant progress in developing briquilimab for chronic inducible urticaria, demonstrating robust efficacy and a favorable safety profile. The company is poised to advance its clinical programs, addressing a critical gap in treatment options for patients suffering from mast cell-driven diseases.